[junkie-button url=”https://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
[shareaholic app=”share_buttons” id=”26934843″]
QOL Medical LLC, a rare-disease pharmaceutical company, today announced the launch of a first-of-its-kind app, GSID AR, providing users with augmented reality (AR) technology to explore both a healthy digestive system and one with Genetic Sucrase-Isomaltase Deficiency (GSID).
Augmented Reality is the integration of digital information with the user’s environment in real time. Unlike Virtual Reality apps that replace the user environment with computer-generated images, the AR experience can be achieved with no dedicated gear; all you need is a smartphone or tablet.
QOL’s Vice President of Marketing, Anthony D’Elia highlights, “As we know AR is all the rage. For an orphan pharmaceutical company, QOL is truly ahead of the curve on this one. The GSID AR App will allow both doctors and patients to experience an in-depth look at this rare disease. With the aid of augmented reality, we can peel away the layers to peek inside the human body to reveal what exactly is going on in there. It’s just so cool.” D’Elia adds, “No glasses or headgear required! I’m sure our doctors and patients alike will love this new learning tool.
QOL’s target audience is the physicians and medical professionals who treat GI (stomach) diseases and conditions but who might not be aware of GSID. “We are dedicated to ongoing innovation to help both educate and increase awareness of GI-based, rare diseases in user-friendly ways,” D’Elia concluded.